Osteoporosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Type (Parathyroid Hormone Therapy, Bisphosphonates, Calcitonin, Selective Estrogen Receptor Modulators, and Other Drug Types), By Route of Administration (Oral, Injectables, Others), By Application (Primary Osteoporosis and Secondary Osteoporosis), By Distribution Channel (Hospit
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationOsteoporosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Type (Parathyroid Hormone Therapy, Bisphosphonates, Calcitonin, Selective Estrogen Receptor Modulators, and Other Drug Types), By Route of Administration (Oral, Injectables, Others), By Application (Primary Osteoporosis and Secondary Osteoporosis), By Distribution Channel (Hospit
| Forecast Period | 2024-2028 |
| Market Size (2022) | USD 16.09 Billion |
| CAGR (2023-2028) | 5.73% |
| Fastest Growing Segment | Online Pharmacy |
| Largest Market | North America |
Market Overview
Key Market Drivers
Increasing Incidences of Osteoporosis
Growing Clinical Trials and Rising Geriatric Population
Improved Awareness and Diagnosis
The Growing Investments in Research and Development
Key Market Challenges
Stringent Regulatory Environment
High Costs Of Treatment
Key Market Trends
Precision Medicine
Novel Drug Targets
Segmental Insights
Route of Administration Insights
Based on the route of administration, the market for osteoporosis is segmented into oral, injectable, and others. Oral drugs are known for being cost-effective and safe, although they may have mild side effects. Rare serious effects, such as osteonecrosis of the jaw, have been reported. However, in terms of effectiveness, oral medications have proven successful in treating osteoporosis. For instance, alendronate (Fosamax) has shown its ability to reduce the risk of hip fractures by 50%. Notably, patients commonly prefer oral drugs due to their convenience and the avoidance of injections or infusions, as indicated by studies focusing on patient preferences. This preference highlights the importance of oral medications in the management of osteoporosis.
Injectable drugs like denosumab (Prolia) have emerged as highly effective options with immediate effects for treating osteoporosis. These medications, while generally safe, do come with the potential for mild side effects. Additionally, there is a rare but serious risk of osteonecrosis of the jaw (ONJ) associated with their use. Despite these considerations, the patent protection granted to these injectable drugs ensures exclusivity, allowing manufacturers to set higher prices. To further maximize their market presence, manufacturers heavily invest in marketing efforts, which in turn influence prescribing patterns. Interestingly, brand loyalty among patients continues to drive the Osteoporosis Drugs Market, even in the presence of alternative treatment options.
Drug Type Insights
In terms of Drug Type, the bisphosphonates accounted for a significant share of the osteoporosis drugs market in 2022. This can be attributed to the increased investment in research and development of advanced novel bisphosphonates drugs by major players in the pharmaceutical industry. Moreover, bisphosphonates are widely prescribed drugs for the treatment of osteoporosis, which further drives the growth of the market.
On the other hand, the rank ligand inhibitors segment is projected to witness the fastest growth rate during the forecast period. This is primarily due to the fact that these drugs are specifically used to treat bone metastasis by acting as a chemoattractant to bone for tumor cells expressing its receptor, RANK. As a result, the inhibition of the RANKL-RANK pathway serves as an ideal treatment approach for bone metastasis. The detailed understanding and utilization of these drug types contribute to the advancement of osteoporosis treatment, ultimately improving the quality of life for patients affected by this condition.
Regional Insights
Recent Developments
- In May 2023, a recent real-world studyinvolving nearly half a million postmenopausal women with osteoporosis in theU.S. Medicare program revealed that Prolia (denosumab) injection demonstrated areduction in fracture risk when compared to oral alendronate, a commonlyprescribed bisphosphonate medication. Furthermore, the long-term use of Proliawas associated with significant decreases in the risk of fractures.
- In August 2021, Enzene Biosciences Ltd obtainedMarketing Authorization (MA) from the Drug Controller General of India (DCGI)for its biosimilar drug, denosumab. This particular drug is indicated for thetreatment of osteoporosis in adults.
- In January 2021, Livogiva, an osteoporosismedicine, was launched in Europe by Theramex, a pharmaceutical companyheadquartered in London.
Key Market Players
- Eli Lilly and Company
- Pfizer Inc.
- F. Hoffmann-La Roche
- Teva Pharmaceutical IndustriesLtd.
- GlaxoSmithKline plc.
- Novartis International AG
- Merck & Co. Inc.
- Amgen Inc.
- Radius Health Inc.
- Actavis PLC
| By Drug Type | By Route of Administration | By Application | By Distribution Channel | By Region |
|
|
|
|
|
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy